References
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2016. [Last accessed 2016 March 15]. Available from: http://www.goldcopd.org.
- Tuder RM, Petrache I. Pathogenesis of chronic obstructive pulmonary disease. J Clin Invest. 2012;122:2749–2755.
- Liebow AA. Pulmonary emphysema with special reference to vascular changes. Am Rev Respir Dis. 1959;80:67–93.
- Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD study): a population based prevalence study. Lancet. 2007;370:741–750.
- Mannino DM, Homa DM, Akinbami LJ, et al. Chronic obstructive pulmonary disease surveillance-United States, 1971–2000. MMWR Surveill Summ. 2002;51:1–16.
- Anthonisen NR, Skeans MA, Wise RA, et al.; Lung Health Study Research Group. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med. 2005;142:233–239.
- Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest. 2005;127:1952–1959.
- Mannino DM, Buist AS, Petty TL, et al. Lung function and mortality in the United States: data from the first national health and nutrition examination survey follow up study. Thorax. 2003;58:388–393.
- Antonelli-Incalzi R, Imperiale C, Bellia V, et al.; SaRA Investigators. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J. 2003;22:444–449.
- Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life: the Quality of Life of Chronic Obstructive Pulmonary Disease Study Group. Ann Intern Med. 1997;127:1072–1079.
- O’Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease – 2008 update – highlights for primary care. Can Respir J. 2008;15(Suppl A):1A–8A.
- Ramsey S, Sullivan S. Chronic obstructive pulmonary disease: is there a case for early intervention? Am J Med. 2004;117:3S–10S.
- Chapman KR, Tashkin DP, Pye DJ. Gender bias in the diagnosis of COPD. Chest. 2001;119(6):1691–1695.
- Walters JA, Hansen E, Mudge P, et al. Barriers to the use of spirometry in general practice. Aust Fam Physician. 2005;34(3):201–203.
- Walters JA, Hansen EC, Walters EH, et al. Under-diagnosis of chronic obstructive pulmonary disease: a qualitative study in primary care. Respir Med. 2008;102(5):738–743.
- Nishi SP, Wang Y, Kuo YF, et al. Spirometry use among older adults with chronic obstructive pulmonary disease: 1999-2008. Ann Am Thorac Soc. 2013;10(6):565–573.
- CanCOLD Study Group, Van Dijk W, Tan W, Li P, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort. Ann Fam Med 2015;13(1):41–48.
- Wollmer P, Engström G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: an outcome study. Respir Med. 2013;107(9):1460–1462.
- Güder G, Brenner S, Angermann CE, et al. GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study. Respir Res 6. 2012;13(1):13.
- Schermer TRJ, Smeele IJM, Thoonen BPA, et al. Current clinical guideline definitions for airflow obstruction leads to substantial overdiagnosis of COPD in primary care. Eur Respir J. 2008;32:945–952.
- James E, Hansen JE, Sun XG, et al. Spirometric criteria for airway obstruction. Chest. 2007;131:349–355.
- Joo MJ, Au DH, Fitzgibbon ML, et al. Determinants of spirometry use and accuracy of COPD diagnosis in primary care. J Gen Intern Med. 2011;26(11):1272–1277.
- Quanjer PH, Stanojevic S, Cole TJ, et al.; The ERS Global Lung Function Initiative. Multi-ethnic reference values for spirometry for the 3-95 years age range: the Global Lung Function 2012 equations. Eur Respir J. 2012;40:1324–1343.
- Elbehairy AF, Faisal A, Guenette JA, et al.;Canadian Respiratory Research Network. Resting physiological correlates of reduced exercise capacity in smokers with mild airway obstruction. Journal of COPD; COPD. 2017;14(3):267-275.
- Tilert T, Dillon C, Paulose-Ram R, et al. Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the national health and nutrition examination survey (NHANES) 2007-2010. Respir Res 9. 2013;14:103.
- Scholes S, Moody A, Mindell JS. Estimating population prevalence of potential airflow obstruction using different spirometric criteria: a pooled cross-sectional analysis of persons aged 40-95 years in England and Wales. BMJ Open. 2014;4(7):e005685.
- Global Health Epidemiology Reference Group (GHERG), Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: systematic review and meta-analysis. J Glob Health 2015;5(2):020415.
- Bousquet J, Kiley J, Bateman ED, et al. Prioritised research agenda for prevention and control of chronic respiratory diseases. Eur Respir J. 2010;36(5):995–1001.
- Swanney MP, Ruppel G, Enright PL, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046–1051.
- WHO. World health statistics. 2008. [Accessed 2016August 19]. Available at: http://www.who.int/respiratory/copd/burden/en/.
- Guenette JA, Jensen D, Webb KA, et al. Sex differences in exertional dyspnea in patients with mild COPD: physiological mechanisms. Respir Physiol Neurobiol. 2011;177:218–227.
- Chin RC, Guenette JA, Cheng S, et al. Does the respiratory system limit exercise in mild chronic obstructive pulmonary disease? Am J Respir Crit Care Med 15. 2013;187(12):1315–1323. DOI:10.1164/rccm.201211-1970OC
- Ofir D, Laveneziana P, Webb KA, et al. Mechanisms of dyspnea during cycle exercise in symptomatic patients with GOLD stage I chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:622–629.
- Elbehairy AF, Ciavaglia CE, Webb KA, et al., Canadian Respiratory Research Network. Pulmonary gas exchange abnormalities in mild COPD: implications for exercise intolerance. Am J Respir Crit Care Med. 2015;191:1384–1394.
- Guenette JA, Chin RC, Cheng S, et al. Mechanisms of exercise intolerance in global initiative for chronic obstructive lung disease grade 1 COPD. Eur Respir J. 2014;44:1177–1187.
- Elbehairy A, Raghavan N, Cheng S, et al.; Canadian Respiratory Research Network. Physiological characterization of the chronic bronchitis phenotype in GOLD grade 1B COPD. Chest. 2015;147:1235–1245.
- Watz H, Waschki B, Boehme C, et al. Extrapulmonary effects of chronic obstructive pulmonary disease on physical activity: a cross-sectional study. Am J Respir Crit Care Med. 2008;177(7):743–751.
- Pitta F, Troosters T, Spruit MA, et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;171:972–977.
- Diaz AA, Morales A, Diaz JC, et al. CT and physiologic determinants of dyspnea and exercise capacity during the six minute walk test in mild COPD. Respir Med. 2013;107:570–579.
- Bridevaux PO, Gerbase MW, Probst-Hensch NM, et al. Longterm decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD. Thorax. 2008;63:768–774.
- Bridevaux PO, Probst-Hensch NM, Schindler C, et al. Prevalence of airflow obstruction in smokers and never-smokers in Switzerland. Eur Respir J. 2010;36:1259–1269.
- SPIROMICS Research Group, Woodruff PG, Barr RG, Bleecker E, et al. Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med. 2016; 374(19):1811–1821.
- Soumagne T, Laveneziana P, Veil-Picard M, et al. Asymptomatic subjects with airway obstruction have significant impairment at exercise. Thorax. 2016;71(9):804–811.
- Yanai M, Sekizawa K, Ohrui T, et al. Site of airway obstruction in pulmonary disease: direct measurement of intrabronchial pressure. J Appl Physiol. 1992;1985(72):1016–1023.
- Hogg JC, Macklem PT, Thurlbeck WM. Site and nature of airway obstruction in chronic obstructive lung disease. N Engl J Med. 1968;278(25):1355–1360.
- Mead J. The lung’s “quiet zone.”. N Engl J Med. 1970;282:1318–1319.
- McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N Engl J Med. 2011;365(17):1567–1575.
- Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;350(26):2645–2653.
- Saetta M, Di Stefano A, Turato G, et al. CD8_ T-lymphocytes in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:822–826.
- Cosio MG, Hale KA, Niewoehner DE. Morphologic and morphometric effects of prolonged cigarette smoking on the small airways. Am Rev Respir Dis. 1980;122:265_21.
- Ding M, Chen Y, Guan WJ, et al. Measuring airway remodeling in patients with different copd staging using endobronchial optical coherence tomography. Chest. 2016;150(6):1281–1290.
- Black LF, Hyatt RE, Stubbs SE. Mechanism of expiratory airflow limitation in chronic obstructive pulmonary disease associated with a1-antitrypsin deficiency. Am Rev Respir Dis. 1972;105(6):891–899.
- Leaver DG, Tatterfield AE, Pride NB. Contributions of loss of lung recoil and of enhanced airways collapsibility to the airflow obstruction of chronic bronchitis and emphysema. J Clin Invest. 1973;52(9):2117–2128.
- Eltayara L, Ghezzo H, Milic-Emili J. Orthopnea and tidal expiratory flow limitation in patients with stable COPD. Chest. 2001;119(1):99–104.
- Hansen JE, Sun XG, Wasserman K. Discriminating measures and normal values for expiratory obstruction. Chest. 2006;129(2):369–377.
- COPDGene investigators, Dilektasli AG, Porszasz J, Casaburi R, et al. A novel spirometric measure identifies mild copd unidentified by standard criteria. Chest 2016;150(5):1080–1090.
- Corbin RP, Loveland M, Martin RR, et al. A four-year follow-up study of lung mechanics in smokers. Am Rev Respir Dis. 1979;120:293–304.
- Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of varying severity. Copd. 2010;7:428–437.
- Canadian Respiratory Research Network, Elbehairy AF, Guenette JA, Faisal A, et al. Mechanisms of exertional dyspnoea in symptomatic smokers without COPD. Eur Respir J 2016;48(3):694–705.
- Buist AS. Early detection of airways obstruction by the closing volume technique. Chest. 1973;64:495–499.
- Crim C, Celli B, Edwards LD, et al.; ECLIPSE investigators. Respiratory system impedance with impulse oscillometry in healthy and COPD subjects: ECLIPSE baseline results. Respir Med. 2011;105:1069–1078.
- Bickel S, Popler J, Lesnick B, et al. Impulse oscillometry: interpretation and practical applications. Chest. 2014;146(3):841–847.
- Vestbo J, Edwards LD, Scanlon PD, et al.; For the ECLIPSE Investigators. Changes in forced expiratory volume in 1 second overtime in COPD. N Engl J Med. 2011;365:1184–1192.
- Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
- Decramer M, Celli B, Kesten S, et al.; For the UPLIFT investigators. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171–1178.
- COPDGene Investigators, Bhatt SP, Soler X, Wang X, et al. Association between functional small airway disease and fev1 decline in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2016; 194(2):178–184.
- Scanlon PD, Connett JE, Waller LA, et al.; For the Lung Health Study Research Group. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Amj Respir Crit Caremed. 2000;161:381–390.
- Rodriguez-Roisin R, Drakulovic M, Rodriguez DA, et al. Ventilation- perfusion imbalance and chronic obstructive pulmonary disease staging severity. J Appl Physiol. 2009;106(6):1902–1908.
- Barbera JA, Riverola A, Roca J, et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1994;149:423–429.
- Barbera JA, Ramirez J, Roca J, et al. Lung structure and gas exchange in mild chronic obstructive pulmonary disease. Am Rev Respir Dis. 1990;141:895–901.
- Peinado VI, Barbera JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998;274:L908–13.
- Santos S, Peinado VI, Ramirez J, et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J. 2002;19:632–638.
- Estépar RS, Kinney GL, Black-Shinn JL, et al. Computed tomographic measures of pulmonary vascular morphology in smokers and their clinical implications. Am J Respir Crit Care Med. 2013;188(2):231–239.
- Matsuoka S, Yamashiro T, Washko GR, et al. Quantitative CT assessment of chronic obstructive pulmonary disease. Radiographics. 2010;30(1):55–66.
- Gordon C, Gudi K, Krause A, et al. Circulating endothelial microparticles as a measure of early lung destruction in cigarette smokers. Am J Respir Crit Care Med. 2011;184:224–232.
- Thomashow MA, Shimbo D, Parikh MA, et al. Endothelial microparticles in mild chronic obstructive pulmonary disease and emphysema: the multi-ethnic study of atherosclerosis chronic obstructive pulmonary disease study. Am J Respir Crit Care Med. 2013;188:60–68.
- Strulovici-Barel Y, Staudt MR, Krause A, et al. Persistence of circulating endothelial microparticles in COPD despite smoking cessation. Thorax71. 2016;12:1137–1144.
- Wright JL, Churg A. Effect of long-term cigarette smoke exposure on pulmonary vascular structure and function in the guinea pig. Exp. Lung Res. 1991;17:997–1009.
- Hilde JM, Skjorten I, Hansteen V, et al. Haemodynamic responses to exercise in patients with COPD. Eur Respir J. 2013;41:1031–1041.
- Portillo K, Torralba Y, Blanco I, et al. Pulmonary hemodynamic profile in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:1313–1320.
- Kessler R, Faller M, Weitzenblum E, et al. Natural history’ of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med. 2001;164:219–224.
- Gupta NK, Agrawal RK, Srivastav AB, et al. Echocardiographic evaluation of heart in chronic obstructive pulmonary disease patient and its co-relation with the severity of disease. Lung India. 2011;28(2):105–109.
- Wright JL, Lawson L, Paré PD, et al. The structure and function of the pulmonary vasculature in mild chronic obstructive pulmonary disease. Am Rev Respir Dis. 1983;128:702–707.
- Peinado VI, Pizarro S, Barberà JA. Pulmonary vascular involvement in COPD. Chest. 2008;134:808–814.
- Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes: healthy highlanders and chronic mountain sickness. Circulation. 2007;115:1132–1146.
- Seimetz M, Parajuli N, Pichl A, et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell. 2011;147:293–305.
- Ferrer E, Peinado VI, Castan˜eda J, et al. Effects of cigarette smoke and hypoxia on pulmonary circulation in the guinea pig. Eur Respir J. 2011;38:617–627.
- Hoffman D, Hecht S. Advances in tobacco carcinogenesis. In: Cooper CS, Grover PL, editors. Chemical carcinogenesis and mutagenesis I. Handbook of experimental pharmacology. Vol. 94, No. I. Heidelberg: Springer; 1990. p. 63–102.
- Nana-Sinkam SP, Lee JD, Sotto-Santiago S, et al. Prostacyclin prevents pulmonary endothelial cell apoptosis induced by cigarette smoke. Am J Respir Crit Care Med. 2007;175:676–685.
- Chaouat A, Naeije R, Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008;32:1371–1385.
- Nicolls MR, Mizuno S, Taraseviciene-Stewart L, et al. New models of pulmonary hypertension based on VEGF receptor blockade-induced endothelial cell apoptosis. Pulm Circ. 2012;2:434–442.
- Dunham-Snary KJ, Wu D, Sykes EA, et al. Hypoxic pulmonary vasoconstriction: from molecular mechanisms to medicine. Chest. 2017;151(1):181–192.
- Kirby M, Owrangi A, Svenningsen S, et al. On the role of abnormal DL(CO) in ex-smokers without airflow limitation: symptoms, exercise capacity and hyperpolarised heliu-3 MRI. Thorax. 2013;68:752–759.
- Harvey BG, Strulovici-Barel Y, Kaner RJ, et al. Risk of COPD with obstruction in active smokers with normal spirometry and reduced diffusion capacity. Eur Respir J. 2015;46(6):1589–1597.
- Maleki-Yazdi MR, Lewczuk CK, Haddon JM, et al. Early detection and impaired quality of life in COPD GOLD stage 0: a pilot study. Copd 4. 2007;4:313–320.
- Watz H, Waschki B, Meyer T, et al. Physical activity in patients with COPD. Eur Respir J. 2009;33(2):262–272.
- Yuan R, Hogg JC, Pare PD, et al. Prediction of the rate of decline in FEV1 in smokers using quantitative computed tomography. Thorax. 2009;64(11):944–949.
- Rambod M, Porszasz J, Make BJ, et al. Six-minute walk distance predictors, including CT scan measures, in the COPDGene cohort. Chest. 2012;141(4):867–875.
- Genetic Epidemiology of COPD (COPDGene) Investigators, Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and radiologic disease in smokers with normal spirometry. JAMA Intern Med 2015;175(9):1539–1549.
- Grydeland TB, Dirksen A, Coxson HO, et al. Quantitative computed tomography measures of emphysema and airway wall thickness are related to respiratory symptoms. Am J Respir Crit Care Med. 2010;181(4):353–359.
- Martinez CH, Chen YH, Westgate PM, et al. Relationship between quantitative CT metrics and health status and BODE in chronic obstructive pulmonary disease. Thorax. 2012;67(5):399–406.
- Diaz AA, Bartholmai B, San José Estépar R, et al. Relationship of emphysema and airway disease assessed by CT to exercise capacity in COPD. Respir Med. 2010;104(8):1145–1151.
- ECLIPSE Investigators, Gietema HA, Edwards LD, Coxson HO, et al. Impact of emphysema and airway wall thickness on quality of life in smoking-related COPD. Respir Med. 2013;107(8):1201–1209.
- Dransfield MT, Huang F, Nath H, et al. CT emphysema predicts thoracic aortic calcification in smokers with and without COPD. Copd. 2010;7(6):404–410.
- Mathew L, Kirby M, Etemad-Rezai R, et al. Hyperpolarized 3He magnetic resonance imaging: preliminary evaluation of phenotyping potential in chronic obstructive pulmonary disease. Eur J Radiol. 2011;79(1):140–146.
- Woods JC, Choong CK, Yablonskiy DA, et al. Hyperpolarized 3He diffusion MRI and histology in pulmonary emphysema. Magn Reson Med. 2006;56(6):1293–1300.
- Diaz S, Casselbrant I, Piitulainen E, et al. Validity of apparent diffusion coefficient hyperpolarized (3) He-MRI using MSCT and pulmonary function tests as references. Eur J Radiol. 2009;71(2):257–263.
- Canadian Respiratory Research Network, Davis C, Sheikh K, Pike D, et al. Ventilation heterogeneity in never-smokers and COPD: comparison of pulmonary functional magnetic resonance imaging with the poorly communicating fraction derived from plethysmography. Acad Radiol 2016;23(4):398–405.
- Kirby M, Pike D, Sin DD, et al. COPD: do imaging measurements of emphysema and airway disease explain symptoms and exercise capacity? Radiology. 2015;277(3):872–880.
- Hueper K, Vogel-Claussen J, Parikh MA, et al. Pulmonary microvascular blood flow in mild chronic obstructive pulmonary disease and emphysema. The MESA COPD Study. Am J Respir Crit Care Med. 2015;192(5):570–580.
- Fan L, Xia Y, Guan Y, et al. Capability of differentiating smokers with normal pulmonary function from COPD patients: a comparison of CT pulmonary volume analysis and MR perfusion imaging. Eur Radiol. 2013;23:1234–1241.
- Xia Y, Guan Y, Fan L, et al. Dynamic contrast enhanced magnetic resonance perfusion imaging in high-risk smokers and smoking-related COPD: correlations with pulmonary function tests and quantitative computed tomography. Copd. 2014;11:510–520.
- ZuWallack R. How are you doing? What are you doing? Differing perspectives in the assessment of individuals with COPD. Copd. 2007;4:293–297.
- Neder JA, Arbex FF, Alencar MC, et al. Exercise ventilatory inefficiency in mild to end-stage COPD. Eur Respir J. 2015;45:377–387.
- Wasserman K, Hansen J, Sue DY, et al. Principles of exercise testing and interpretation. 3rd. Baltimore, MD: Lippincott, Williams and Wilkins; 1999.
- Preston M, Cheng S, Ling Y, et al. Comparison of ventilatory control characteristics in mild COPD and in health. B110. Upper Airway and Respiratory Control during Sleep. 2014 May 1;A3891–A3891.
- Malerba M, Ragnoli B, Salameh M, et al. Sub-clinical left ventricular diastolic dysfunction in early stage of chronic obstructive pulmonary disease. J Biol Regul Homeost Agents. 2011;25(3):443–451.
- Sabit R, Bolton CE, Fraser AG, et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010;104(8):1171–1178.
- Vonk-Noordegraaf A, Marcus JT, Holverda S, et al. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest. 2005;127(6):1898–1903.
- Seymour JM, Spruit MA, Hopkinson NS, et al. The prevalence of quadriceps weakness in COPD and the relationship with disease severity. Eur Respir J. 2010;36(1):81–88.
- Kharbanda S, Ramakrishna A, Krishnan S. Prevalence of quadriceps muscle weakness in patients with COPD and its association with disease severity. Int J Chron Obstruct Pulmon Dis. 2015;10:1727–1735.
- Barbera JA, Roca J, Ramirez J, et al. Gas exchange during exercise in mild chronic obstructive pulmonary disease. Correlation with lung structure. Am Rev Respir Dis. 1991;144(3 Pt 1):520–525.
- O’Donnell DE. Ventilatory limitations in chronic obstructive pulmonary disease. Med Sci Sports Exerc. 2001;33(7 Suppl):S647–655.
- Potter WA, Olafsson S, Hyatt RE. Ventilatory mechanics and expiratory flow limitation during exercise in patients with obstructive lung disease. J Clin Invest. 1971;50:910–919.
- Stubbing DG, Pengelly LD, Morse JL, et al. Pulmonary mechanics during exercise in subjects with chronic airflow obstruction. J Appl Physiol Respir Environ Exerc Physiol. 1980;49(3):511–515.
- O’Donnell DE, Laveneziana P, Ora J, et al. Evaluation of acute bronchodilator reversibility in patients with symptoms of GOLD stage I COPD. Thorax. 2009;64:216–223.
- Casaburi R, Rennard SI. Exercise limitation in chronic obstructive pulmonary disease. The O’Donnell Threshold. Am J Respir Crit Care Med. 2015;191(8):873–875.
- O’Donnell DE, Laveneziana P. Physiology and consequences of lung hyperinflation in COPD. Eur Respir Rev. 2006;15(100):61–67.
- Voelkel NF, Cool CD. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Eur Respir J. 2003;46:28s–32s.
- Barr RG. The epidemiology of vascular dysfunction relating to chronic obstructive pulmonary disease and emphysema. Proc Am Thorac Soc. 2011;8:522–527.
- Luo YM, Moxham J, Polkey MI. Diaphragm electromyography using an oesophageal catheter: current concepts. Clin Sci (Lond). 2008;115(8):233–244.
- Laveneziana P, Webb KA, Ora J, et al. Evolution of dyspnea during exercise in chronic obstructive pulmonary disease: impact of critical volume constraints. Am J Respir Crit Care Med. 2011;184:1367–1373.
- Pleguezuelos E, Esquinas C, Moreno E, et al. Muscular dysfunction in COPD: systemic effect or deconditioning? Lung. 2016;194:249–257.
- Montes De Oca M, Loeb E, Torres SH, et al. Peripheral muscle alterations in non-COPD smokers. Chest. 2008;133:13–18.
- Wǘst RC, Jaspers RT, Van Der Laarse WJ, et al. Skeletal muscle capillarization and oxidative metabolism in healthy smokers. Appl Physiol Nutr Metab. 2008;33:1240–1245.
- Morse CI, Wüst RC, Jones DA, et al. Muscle fatigue resistance during stimulated contractions is reduced in young male smokers. Acta Physiol (Oxf). 2007;191(2):123–129.
- Patessio A, Casaburi R, Carone M, et al. Comparison of gas exchange, lactate, and lactic acidosis thresholds in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis. 1993;148:622–626.
- Mannino DM, Doherty DE, Buist AS. Global initiative on obstructive lung disease (GOLD) classification of lung disease and mortality: findings from the atherosclerosis risk in communities (ARIC) study. Respir Med. 2006;100:115–122.
- Smith BM, Kawut SM, Bluemke DA, et al. Pulmonary hyperinflation and left ventricular mass: the multi-ethnic study of atherosclerosis COPD study. Circulation. 2013;127(14):1503–1511.
- Grau M, Barr RG, Lima JA, et al. Percent emphysema and right ventricular structure and function: the MESA lung and MESARV studies. Chest. 2013;144(1):136–144.
- Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010;362(3):217–227.
- Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev. 2013;22(130):454–475.
- Sin DD, Anthonisen NR, Soriano JB, et al. Mortality in COPD: the role of comorbidities. Eur Respir J. 2006;28(6):1245–1257.
- McAllister DA, Maclay JD, Mills NL, et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;176:1208–1214.
- Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:1259–1265.
- Iwamoto H, Yokoyama A, Kitahara Y, et al. Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med. 2009;179:35–40.
- Gao Y, Du X, Qin W, et al. Assessment of the right ventricular function in patients with chronic obstructive pulmonary disease using MRI. Acta Radiol. 2011;52:711–715.
- Bernardi L, Casucci G, Haider T, et al. Autonomic and cerebrovascular abnormalities in mild COPD are worsened by chronic smoking. Eur Respir J. 2008;32(6):1458–1465.
- Agusti A, Soriano JB. COPD as a systemic disease. Copd. 2008;5(2):133–138.
- Montes De Oca M, Torres SH, De Sanctis J, et al. Skeletal muscle inflammation and nitric oxide in patients with COPD. Eur Respir J. 2005;26:390–397.
- Sin DD, Reid WD. Is inflammation good, bad or irrelevant for skeletal muscles in COPD? Thorax. 2008;63(2):95–96.
- Contreras-Shannon V, Ochoa O, Reyes-Reyna SM, et al. Fat accumulation with altered inflammation and regeneration in skeletal muscle of CCR2-/- mice following ischemic injury. Am J Physiol Cell Physiol. 2007;292:C953–67.
- Ottenheijm CA, Heunks LM, Sieck GC, et al. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):200–205.
- Maltais F, LeBlanc P, Jobin J, et al. Peripheral muscle dysfunction in chronic obstructive pulmonary disease. Clin Chest Med. 2000;21:665–677.
- Maltais F, LeBlanc P, Whittom F, et al. Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD. Thorax. 2000;55:848–853.
- Skeletal muscle dysfunction in chronic obstructive pulmonary disease. A statement of the American thoracic society and European Respiratory Society. Am J Respir Crit Care Med. 1999;159:S1–S40.
- Lindberg A, Larsson LG, Rönmark E, et al. Comorbidity in mild-to-moderate COPD: comparison to normal and restrictive lung function. Copd. 2011;8:421–428.
- Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis. 1993;147:1151–1156.
- Lung Health Study Research Group, Scanlon PD, Connett JE, Wise RA, et al. Loss of bone density with inhaled triamcinolone in Lung Health Study II. Am J Respir Crit Care Med 2004;170(12):1302–1309.
- Rutten EP, Breyer MK, Spruit MA, et al. Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease. Clin Nutr. 2010;29:756–760.
- Pelkonen M, Tukiainen H, Tervahauta M, et al. Pulmonary function, smoking cessation and 30 year mortality in middle aged Finnish men. Thorax. 2000;55:746–750.
- Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397–403.
- Nichol KL, Baken L, Wuorenma J, et al. The health and economic benefits associated with pneumococcal vaccination of elderly persons with chronic lung disease. Arch Intern Med. 1999;159:2437–2442.
- Lacasse Y, Wong E, Guyatt GH, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet. 1996;348:1115–1119.
- Takigawa N, Tada A, Soda R, et al. Comprehensive pulmonary rehabilitation according to severity of COPD. Respir Med. 2007;101:326–332.
- Berry MJ, Rejeski WJ, Adair NE, et al. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med. 1999;160:1248–1253.
- Salman GF, Mosier MC, Beasley BW, et al. Rehabilitation for patients with chronic obstructive pulmonary disease. Meta-analysis of randomized controlled trials. J Gen Intern Med. 2003;18(3):213–221.
- Jacome C, Marques A. Pulmonary rehabilitation for mild COPD: a systematic review. Respir Care. 2014;59:588–594.
- Gagnon P, Saey D, Provencher S, et al. Walking exercise response to bronchodilation in mild COPD: a randomized trial. Respir Med. 2012;106:1695–1705.
- O’Donnell DE, Maltais F, Porszasz J, et al. The continuum of physiological impairment during treadmill walking in patients with mild-to-moderate COPD: patient characterization phase of a randomized clinical trial. Plos One. 2014;9(5):e96574.
- Casaburi R, Maltais F, Porszasz J, et al.; On behalf of the 205.440 Investigators. Effects of tiotropium on hyperinflation and treadmill exercise tolerance in mild to moderate chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2014;11:1351–1361.
- Pauwels RA, Löfdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European respiratory society study on chronic obstructive pulmonary disease. N Engl J Med. 1999;340(25):1948–1953.
- Vestbo J, Sørensen T, Lange P, et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 1999;353(9167):1819–1823.
- Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest. 2013;144(1):106–118.
- Wedzicha JA, Calverley PM, Rabe KF. Roflumilast: a review of its use in the treatment of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:81–90.
- Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2002;166(3):329–332.
- Alcaide AB, Sanchez-Salcedo P, Bastarrika G, et al. Clinical features of smokers with radiological emphysema but without airway limitation. Chest. 2017;151(2):358–365.
- Hirai DM, Jones JH, Zelt JT, et al. Oral N-acetylcysteine and exercise tolerance in mild chronic obstructive pulmonary disease. J Appl Physiol (1985). 2017;122(5):1351-1361.
- Yang L, Cheriyan J, Gutterman DD, et al. Mechanisms of vascular dysfunction in COPD and effects of a novel soluble epoxide hydrolase inhibitor in smokers. Chest. 2017;151(3):555–563.